On June 5, 2026, Aphranel® marked its first anniversary by announcing via PR Newswire that its MagiCCrystal CaHA Filler had received EU MDR (Medical Device Regulation, 2017/745) certification, alongside the launch of its new Arc™ product line, with cumulative commercial deliveries exceeding 150,000 syringes.
Public records indicate that Aphranel® is the first CaHA microsphere-based facial filler to obtain Class III medical device approval from China’s National Medical Products Administration (NMPA). Acquiring EU MDR certification one year post-launch represents a noteworthy milestone for China’s domestic CaHA filler sector.
Why the EU MDR Matters
The EU MDR is the current regulatory framework for medical devices in the European Union, enforcing stringent requirements on technical documentation, clinical evaluation, quality management, post-market surveillance, and traceability. Compared to the legacy MDD framework, the MDR imposes more detailed compliance demands on high-risk devices and places greater emphasis on continuous post-market supervision.
The entry of injectable facial fillers into the EU MDR framework means that manufacturers must not only complete the initial product registration but also continuously address requirements such as clinical evidence, quality systems, the appointment of a Person Responsible for Regulatory Compliance (PRRC), European authorized representatives, and Post-Market Clinical Follow-up (PMCF).
Consequently, Aphranel®’s MDR certification is more than just securing an overseas certificate. It indicates that China’s CaHA fillers are beginning to align with more demanding international regulatory environments.
150,000 Syringes Delivered: A Practical Indicator
Another notable figure in the announcement is the delivery of over 150,000 syringes.
In China, CaHA-based fillers are not a category that is easily or rapidly adopted. Compared with hyaluronic acid fillers, CaHA-based fillers require more physician training, clearer understanding of appropriate use scenarios, and ongoing market education. Achieving this volume of deliveries within a year of launch suggests that the category has transitioned into real-world professional use rather than remaining a theoretical topic.
For the industry, the significance of this milestone is not about whether a specific brand is trending; it is that China’s CaHA products are beginning to move through a more complete path: domestic registration, commercial delivery, product iteration, and now EU market access.
A New Stage for China’s CaHA Products
For a long time, CaHA fillers were largely viewed as a niche segment led by international brands. Aphranel®’s progress shows that Chinese brands are now entering this category with their own products and regulatory pathways, while also taking steps toward international markets.
At the same time, this development should not be overinterpreted. Aphranel®’s MDR certification is a regulatory achievement for a specific brand and a specific product system. It does not mean that all CaHA fillers have received the same level of international recognition. More accurately, it provides an observable example for China’s CaHA product sector: the path from domestic approval to overseas access is now being pioneered.
As CaHA products enter a more mature stage of commercial competition, future differentiation may depend on more than a single product claim. Registration capability, manufacturing management, physician education, clinical-use feedback, and international market operations will all become part of the long-term competition.
The information disclosed on Aphranel®’s first anniversary suggests that China’s CaHA filler segment has moved beyond early approval and is entering a more practical stage of market validation.
This article is an industry news review based on publicly available information. It discusses medical-aesthetic material industry developments only and does not provide recommendations for specific medical products, clinical indications, or treatment decisions.
References
- PR Newswire. Aphranel® Marks First Anniversary with EU MDR Certification, Arc™ Launch, and Over 150,000 Syringes Delivered. June 5, 2026.